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Regulation of nuclear receptor (NR) activity is driven
by alterations in the conformational dynamics of the
receptor upon ligand binding. Previously, we demon-
strated that hydrogen/deuterium exchange (HDX)
can be applied to determine novel mechanism of
action of PPARg ligands and in predicting tissue
specificity of selective estrogen receptor modula-
tors. Here, we applied HDX to probe the conforma-
tional dynamics of the ligand binding domain (LBD)
of the vitamin D receptor (VDR) upon binding its
natural ligand 1a,25-dihydroxyvitamin D3 (1,25D3),
and two analogs, alfacalcidol and ED-71. Compar-
ison of HDX profiles from ligands in complex with
the LBD with full-length receptor bound to its
cognate receptor retinoid X receptor (RXR) revealed
unique receptor dynamics that could not be inferred
from static crystal structures. These results demon-
strate that ligands modulate the dynamics of the
heterodimer interface as well as provide insight into
the role of AF-2 dynamics in the action of VDR partial
agonists.
INTRODUCTION
The vitamin D receptor (VDR) is a ligand-dependent transcription
factor and member of the nuclear receptor (NR) superfamily
(Evans, 1988) that classically functions as a heterodimerwith reti-
noid X receptor a (RXRa) (Forman et al., 1995) to control expres-
sion of genes traditionally associated with the regulation of
mineral homeostasis. However, the scope of VDR biology has
now been implicated in a wide range of physiological cellular
responses including proliferation, differentiation, and immuno-
modulation (Nagpal et al., 2005). The heterodimeric receptor
complex is activated upon binding to 1a,25-dihydroxyvitamin
D3 (1,25D3), the active formof vitamin D. Upon binding to vitamin
D response elements (VDRE) on VDR target genes, liganded
heterodimer recruits or dissociates coactivator/corepressor1332 Structure 18, 1332–1341, October 13, 2010 ª2010 Elsevier Ltdproteins that ultimately modulate the transcriptional output of
the complex.Wheremolecular detail of VDR/RXR transactivation
has been described, the chromatin environment, interacting
protein partners, and temporal kinetics in and around the DNA-
bound VDR/RXR complex can be highly diverse depending on
the genomic target and cellular context in which such regulation
is occurring (Meyer et al., 2007).
In addition to itswell-described transcriptional regulation activ-
ities, VDR also displays the ability to rapidly initiate several key
signal transduction pathways in a ligand-dependent manner
that does not require RXR (Mizwicki and Norman, 2009). These
rapid signaling events appear to be initiated by ligand-bound
VDR outside the nucleus perhaps within cytoplasmic signaling
complexes at or near the plasmamembrane. These nongenomic
activities of VDR may occur via ligand-dependent recruitment of
various cointeracting proteins in this cellular locale alongwith the
appropriate ligand-induced VDR conformation (Mizwicki et al.,
2004; Norman et al., 2004). Mizwicki and Norman (2009) have
recently put forth a structural ensemble model to explain the
mechanistic distinction between genomic versus nongenomic
activities. However, this model remains to be empirically proved.
The VDR agonist 1,25D3 is used clinically for the treatment of
renal osteodystrophy, osteoporosis, psoriasis, cancer, autoim-
mune diseases, and prevention of graft rejection. However, its
therapeutic applications have been limited due to untoward
effects associated with hypermineralization. As a result, drug
discovery efforts have been focused on the development VDR
ligands with improved side effect profile while maintaining
maximal efficacy. One such ligand, the synthetic 1,25D3 analog
alfacalcidol (1-hydroxycholecalciferol), was developed, and it
was determined that in vivo this analog is converted rapidly to
1,25D3 via 25-hydroxylase-mediated 25-hydroxylation primarily
in liver and bone (Nishii, 2003). While it has been reported that
alfacalcidol offers an improved therapeutic index, and as such,
has been approved for treatment of osteoporosis in Japan and
Europe (Cheskis et al., 2006), it is likely that alfacalcidol is
a short-lived prodrug rapidly converted to 1,25D3. Thus, clinical
differentiation of 1,25D3 and alfacalcidol in vivo is likely due to
differences in pharmacokinetic/pharmacodynamic (PK/PD)
profiles of these two compounds.
Drug discovery efforts also lead to the development of ED-71,
a VDR ligand which has been shown in vivo to have lessAll rights reserved
Figure 1. VDR Ligands and Transcriptional Responses
(A) Chemical structures of the ligands.
(B) HEK293 T cells were transfected with the 4xVDRE reporter plasmid and VDR-FL or empty vector and treated with different VDR modulators (10 and 100 nM)
or DMSO.
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HDX Reveals Modulator-Receptor Interactionshypercalcemia liability than 1,25D3 (Cheskis et al., 2006). While
1,25D3 and ED-71 have very similar chemical structures
(Figure 1A) and comparable binding affinities for VDR, they afford
distinct pharmacological profiles both in cellular and animal
models. Ligand activation of NRs involves both ligand binding
and ligand-induced conformational change of the receptor
surface to facilitate cofactor protein interaction. This would
suggest that the different pharmacology observed for ED-71 is
related to the subtle changes in the chemical structure of the
ligand leading to differences in protein-ligand contacts within
the ligand binding pocket (LBP) imparting distinct conformations
of the receptor-ED-71 complex. These distinct receptor-ligand
complexes (VDR-1,25D3 and VDR-ED-71) would differentially
interact with the milieu of cofactor proteins resulting in differ-
ences in transcriptional output following ligand treatment. As
such, analysis of the molecular details of these conformational
changes and subsequent interactions could provide an avenue
for the development of VDR ligands with improved therapeutic
index. The unique biological and pharmacological behavior of
VDR ligands such as ED-71 has led to their classification as
selective VDR modulators or VDRMs (Ma et al., 2006).
Hydrogen/deuterium exchange (HDX) particularly when
coupled with mass spectrometry (MS) has emerged as a rapid
and sensitive approach for characterization of protein folding,
protein-protein interactions, and protein-ligand interactions
and has been proved to provide complementary information to
that gained via X-ray crystallography (Chandra et al., 2008;
Hamuro et al., 2006; Hsu et al., 2009; Iacob et al., 2009). Our
laboratory and others have successfully applied HDX to mecha-
nistic analysis of NR activation (Bruning et al., 2007; Chalmers
et al., 2007; Dai et al., 2008, 2009; Hamuro et al., 2003, 2006;Structure 18, 1332–1Yan et al., 2004, 2007). In one example, we described a novel
mechanism of ligand activation of PPARg (peroxisome prolifera-
tor-activated receptor gamma) where different binding modes
were detected for full agonists as compared to partial agonists
and that partial agonists activate the receptor in a helix 12 inde-
pendent fashion relying on stabilization of other regions of the
LBP (Bruning et al., 2007). In another example, we applied
HDX to classify various selective ERa modulators (SERMs)
based on their HDX signatures, and these signatures were deter-
mined to be correlative to the pharmacology observedwith these
ligands in both preclinical and clinical settings (Dai et al., 2008).
Most recently, we used HDX to reveal unique binding patterns
of estrogens to ERa and ERb (Dai et al., 2009). Although these
studies were performed with isolated ligand binding domains
(LBDs) of the specific NR, HDX analysis of intact PPARg/RXRa
heterodimer was published along with the crystal structure of
the intact complex (Chandra et al., 2008). The HDX profile of
PPARg in the intact complex is in good agreement with that
previously published for the LBD.
Basedon theseprevious studies,wepostulated thatHDXanal-
ysiswould provide insight into themechanismof ligand activation
of the vitamin D receptor. To this end, we used HDX to probe the
conformational dynamics of the LBD of VDR in complex with
three ligands, 1,25D3, ED-71, and alfacalcidol. To examine the
impact of the presence of the cognate coreceptor on ligand-
induced dynamics of VDR, HDX profiles were also obtained
with these ligands in complex with full-length VDR/RXRa.
Comparison of the HDX profiles from ligands described above
in complex with the VDR LBD to profiles obtained on full-length
receptor heterodimerized with RXR revealed unique receptor
dynamics that could not be inferred from static crystal341, October 13, 2010 ª2010 Elsevier Ltd All rights reserved 1333
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modulate the dynamics of the VDR/RXR heterodimer interface
as well as provide insight into the role of AF-2 dynamics in the
action of VDR partial agonists. Furthermore, we demonstrate
that these HDX profiles are predictive of the ligand-dependent
functional behavior of VDR/RXRa in cofactor peptide interaction
assays and cell-based transactivation activities.
RESULTS
Characterization of VDR Ligands
Cell-based reporter gene assays were used to assess the
transcriptional potency and efficacy of 1,25D3, ED-71 and alfa-
calcidol ligands. Treatment of HEK293T cells transfected with
a multimerized 4xVDRE luciferase reporter with 1,25D3 (10 nM)
resulted in weak transactivation (1.6-fold over DMSO only;
Figure 1B) of luciferase. Under the same conditions, 10 nM
ED-71 and alfacalcidol failed to stimulate expression of the
reporter. The poor response of the reporter in this system likely
reflects the lowexpressionof theVDR in thesecells. Asexpected,
treatment of cells cotransfected with reporter and wild-type VDR
with 10 nM 1,25D3 resulted in robust transactivation of luciferase
(10-fold over DMSO only; Figure 1B). Under the same condi-
tions, treatment with ED-71 (10 nM) and alfacalcidol (10 nM) re-
sulted in 7- and 2-fold induction of the reporter, respectively, as
comparedwithDMSOonly (Figure 1B). Increasing the concentra-
tion of the ligands to 100 nM reveals that ED-71 reachesmaximal
efficacy matching that of 1,25D3 while the maximal induction of
alfacalcidol is approximately 20% lower (Figure 1B).
We next examined the ability of these three ligands to modu-
late the ability of VDR to interact with an array of cofactor protein
fragments using a biochemical assay. The cofactor peptide
library, made up predominately of LXXLL-containing motifs,
was designed from a full range of VDR interacting proteins
including those of DRIP/TRAP and the p160 coactivator family.
We utilized luminex-based xMAP technology to assess the
global peptide interaction capacity while Alphascreen tech-
nology was used to quantify DRIP205-2 and SRC-1 NR2 peptide
interactions independently. Importantly, both luminex and
Alphascreen reactions were constructed such that signal was
dependent on the formation of the heterodimer complex via
Flag-hRXRa, as this was the source of signal generation in
both settings. Controls were performed to verify that data gener-
ated were dependent on the presence of the heterodimer partner
and could not be a function of homodimerization by either RXRa
or VDR (data not shown).
Upon addition of saturating concentrations of each ligand
(1 mM) to the VDR and RXRa containing reaction, a highly signif-
icant but wide range of cofactor peptide interactions occurred
across the peptide spectrum (Figure 2A). Most notably, the
DRIP205, PGC-1, SRC, RIP140, and SHP/DAX peptide interac-
tionswere significantly drivenbybothED-71and1,25D3. Interes-
tingly, while the overall peptide interaction fingerprint for ED-71
versus 1,25D3 was very similar, there were subtle differences in
the magnitude of the various peptide interactions between these
two ligands. However, alfacalcidol-bound VDR/RXRa clearly
lacked capacity to drive significant peptide interactions across
the entire peptide spectrum by comparison to ED-71 or 1,25D3
consistent with partial agonist activity. To quantify this ligand1334 Structure 18, 1332–1341, October 13, 2010 ª2010 Elsevier Ltddistinction, Alphascreen technology was used to measure indi-
vidual cofactor peptide affinities for the ligand-bound VDR/
RXRa complex. DRIP205-2 and SRC-1 NR2 cofactor peptides
were chosen and a full concentration range of each ligand was
tested (Figure 2B). Again, both ED-71 and 1,25D3 show robust
but similar ligand and concentration-dependent capacities to
interact with each cofactor peptide. Interestingly, there was
a subtle but significant difference between ED-71- versus
1,25D3-driven interaction with the SRC-1 NR2 peptide where
a greater maximal interaction is achieved with 1,25D3 over ED-
71 (17% difference) while sharing similar potencies (Figure 2B).
In agreement with luminex data (Figure 2A), alfacalcidol displays
partial agonist activity with a reduced efficacy of interaction with
the cofactor peptides (57% and 66% difference by compar-
ison to 1,25D3). Alfacalcidol was also displayed significantly
reduced potency relative to 1,25D3 and ED-71 (Figure 2B). The
lack of the 25-hydroxyl group in alfacalcidol likely plays a critical
role in the partial activity of this compound since the 25-hydroxyl
group of 1,25D3 is known to play a role in positioning of H12
(Rochel et al., 2000). In general, the partial agonist activity of alfa-
calcidol was detected in both the biochemical and cell-based
assays, but thepartial agonist activitywassomewhat lessevident
in the cell-based assay. Since HEK293 cells express vitamin D
25-hydroxylase (CYP2R1) (Cheng et al., 2003, 2004), it is likely
that alfacalcidol is 25-hydroxylated in the cell-based assay
yielding a more efficacious compound than detected in the
biochemical assays.
HDX Analysis of Apo VDR-LBD
The following studies were designed to provide optimal compar-
ison between HDX and co-crystal structures. To that end, the
initial HDX experiments were carried out using the same domain
context as was available in the PBD, which in the case of VDR is
the isolated LBD. Prior to analyzing receptor-ligand complexes,
HDX was used to characterize the conformational dynamics of
the unliganded apo VDR LBD. As was elegantly shown by Eng-
lander and coworkers, the rate of amide hydrogen exchange
with solvent deuterium is highly dependent on local fluctuations
in protein structure (Englander and Kallenbach, 1983). While
there is no published crystal structure of apo VDR LBD, HDX
analysis provides information on the dynamics of functionally
important regions of this domain such as H3 and AF2 (H3-H4
loop and H12) as well as relative dynamics of the LBP. HDX
kinetics for 42 VDR peptic peptides covering 90% of the
construct used in this study (71% of the wt sequence of the
LBD) were measured at specific time points. The average deute-
rium exchange (n = 3) behavior of individual peptic peptides
derived from apo VDR at each time point was overlaid onto the
crystal structure of VDR in complex with 1,25D3 (PDB: 1DB1
with ligand removed to avoid confusion) as shown in Figure 3.
These data show that the entire C-terminal region including the
H11-12 loop is very dynamic with over 80% of amide hydrogens
exchange with 10 s exposure to heavy water. This is consistent
with the fact that for most apo NRs the H11-H12 loop (residues
404–411 in VDR) is highly disordered (random-coil) and H12
(residues 412–419 in VDR), while structured, is assumed highly
dynamic. Peptides derived from regions adjacent to the ‘‘inser-
tion domain’’ (residues 219–224), a region of VDR that is poorly
structured (Rochel et al., 2000), exhibited rapid exchange withAll rights reserved
Figure 2. Quantitative Measurement of Cofactor Peptide Interactions
(A) Full-length human His-VDR and Flag-RXR proteins were added to a multiplexed streptavidin-based bead-bound cassette of biotinylated NHR cofactor
peptides. VDR ligands were added to this mixture at fully saturable concentrations (1 mM) and incubated with shaking for 2 hr. Quantitation of VDR/ligand/
RXR/bead-bound cofactor peptide complexes were measured using xMAP-based BioRad Luminex 120 instrument and Applied Cytometry Systems StarStation
software. Cofactor peptide interactions with VDR/RXR are displayed as a heat map (fold interaction versus the Apo DMSO state) using Spotfire DecisionSuite
software.
(B) Using anti-Flag/streptavidin bead-based alphascreen technology, full-length human His-VDR and Flag-RXR proteins were incubated with either biotinylated
SRC-1 NR2 or DRIP205-2 33-mer cofactor peptides. VDR ligands were added to this mixture with increasing concentration (10 and 100 nM) and after 15 min the
formation of VDR/RXR/peptide complexes were quantified using a Perkin Elmer Envision 2103Multilabel Reader. Data analysis and curve-fitting were performed
using GraphPad Prizm software.
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HDX Reveals Modulator-Receptor Interactionssolvent deuterium. The b sheet region (residues 280–308) was
also found to be highly dynamic, which supports the distinct
characteristics from crystallography of ligand-bound VDR LBD
in that the tip of b sheet is shifted outward to the surface, leading
to a larger LBP (Rochel et al., 2000). Interestingly, most regions
that form the LBP (H1, residues 133–150; H3, residues 225–
233; H5, residues 273–279; H6-H7 and b sheet, residues 280–
308; H11, residues 391–403;) had reached maximal on-
exchange within 30 s. This property may correspond to the plas-
ticity of the LBP needed to undergo a large local fluctuation to
accommodate ligand insertion and binding (Yan et al., 2004).
Not all of the LBD was found to be highly dynamic as slow
exchanging regions were found mainly in the central core of
the sandwich structure of the protein with the exception of H5
(residues 273–279) which exhibited fast exchange. The peptides
derived from the region covering 352–365 were protected from
exchange even after 5 min incubation (only <5% exchanged),
revealing that this region is highly ordered. Regions remote of
the central layer of the sandwich structure were also protected
from exchange such as H10 (residues 384–391), where maximalStructure 18, 1332–1exchange over the duration of the experiment was less than
15%. A movie illustrating the exchange behavior of apo VDR
LBD versus time is provided in the Supplemental Information
available online.
Differential HDX Analyses of VDR LBD/Ligand
Complexes
To understand how ligandsmediate the transcriptional activation
of VDR, we performed comprehensive differential HDX analysis
of the VDR LBD in the presence and absence of ligand. This
approach provides a measure of the localized ligand-induced
perturbation in the conformational dynamics of the receptor.
HDX kinetics of peptic peptides derived from the VDR LBD
were measured and the average difference in percentage of
incorporated deuterium between apo VDR LBD and ligand-
bound VDR LBD for the triplicate analysis of six on-exchange
time points (see Experimental Procedures) are presented in
Table 1. A negative value represents an increase in protection
to exchange (less dynamic) in that region of the LBDwhen bound
to ligand as compared with apo, whereas a positive value341, October 13, 2010 ª2010 Elsevier Ltd All rights reserved 1335
Figure 3. Dynamics of apo VDR-LBD
The percentage of deuterium levels for all peptides
of apo VDR-LBD is mapped with color for each
exchange point onto PDB: 1DB1; the color code
is explained at the bottom of the figure. Regions
colored as white represent peptide are not
detected.
See also Movie S1.
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HDX Reveals Modulator-Receptor Interactionsrepresents a decrease in protection to exchange (more dynamic)
in that region of the LBDwhen bound to ligand as compared with
apo. All of the underlying percentage deuterium (D %) versus
time (log scale) plots for all peptides displayed in Table 1 are dis-
played in Figure S2. Plots that show statistically significant differ-
ential HDX dynamics following binding of 1,25D3, ED-71, and al-
facalcidol are indicated as such.
Upon close inspection the differential HDX kinetics induced
by 1,25D3 binding to VDR correlates well with the co-crystal
structure of VDR-LBD/1,25D3 (PDB: 1DB1) (Rochel et al.,
2000). As shown in Table 1 and Figure 4A, there are several
regions within the VDR LBD that afforded dramatic protection
to exchange following binding of 1,25D3. As can be inferred
from PDB:1DB1 H12 (residues 412–419), a region known to be
critical for coactivator binding and transcriptional activity of
the receptor, interacts directly with 1,25D3 by van der Waals
contacts with the methyl group of the ligand and internal interac-
tions with other residues, some of which are directly interacting
with the ligand (Rochel et al., 2000). Consistent with this struc-
ture, H12 showed significant protection to exchange upon
binding 1,25D3. Regions 134–150 (H1), 225–244 (H3), 273–329
(H5-H7), and 391–403 (H11), comprising the ligand-binding
pocket of VDR, showed decreased HDX kinetics, which can
be attributed to hydrogen bonds formed between hydroxyl
groups of 1,25D3 and residues within the LBP. As indicated
by the active conformation of 1,25D3 in the LBP, the 1-OH
group is hydrogen bonded to Ser-237 (H3) and Arg-274 (H5),
the 3-OH group is hydrogen bonded to Ser-278 (H5) and Tyr-
143 (H1), while the 25-OH group forms two hydrogen bonds
with His-305 (loop H6-H7) and His-397 (H11) (Rochel et al.,
2000). It would appear as the entire LBP is capable of forming
a hydrogen bond network with 1,25D3 which would result in1336 Structure 18, 1332–1341, October 13, 2010 ª2010 Elsevier Ltd All rights reservedsignificant protection to exchange in
these regions. In addition, it was ob-
served that regions within the LBP that
make Vander Wall contacts with ligand,
such as L309, were also protected from
exchange. Interestingly, regions remote
of the LBP, such as 317–325 (H7-H8)
and 384–390 (H10), had altered HDX
kinetics, a result that could not have
been predicted from the VDR-LBD/
1,25D3 co-crystal structure. Hel Both of
these two regions are located within the
dimerization interface of the VDR/RXR
complex; thus, we hypothesize that the
ligand-dependent perturbation of this
region impacts VDR interaction with
RXR resulting in an overall stabilizationof the VDR/RXR heterodimer. H10 is the only region of the
LBD that is destabilized upon binding 1,25D3.
ED-71 is a 1,25D3 analog with a hydroxypropoxy group
substituted at position 2 of the A ring (Figure 1A). ED-71 and
1,25D3 share similar HDX signatures (Table 1 and Figure 4;
Figure 2S), which is consistent with the similarities observed by
crystallography (Hourai et al., 2006). In the ED-71 VDR-LBD
co-crystal structure, the position of H12 and the hydrogen bonds
formed between 1-, 3-, 25-hydroxyl groups on the ligands and
individual residuals from LBP are strictly maintained when
compared with VDR/1,25D3 complex. The substitution of the
2-hydroxypropoxy group in ED-71 expels somewater molecules
from the LBP and thus disrupts the ability of Asp-144 in H1 to
form a hydrogen bond with bound water. Disruption of this
water-mediated hydrogen bond was reflected in the magnitude
of HDX protection measured for H1 (Figure S1). Residues
134–150 exhibited a higher protection to exchange for 1,25D3
binding compared with that for ED-71 (29% and 23%, respec-
tively). Although the hydroxypropoxy group makes additional
electrostatic and hydrophobic contacts with H1-loop-H2 and
H3 (consistent with the observation that ED-71 has higher
binding affinity than 1,25D3; Hourai et al., 2006), these contacts
do not compensate for the loss of the hydrogen bond to H1 nor
further stabilize H1-H3. The HDX data presented suggest that
the only region of VDR LBD that undergoes differential confor-
mational dynamics when comparing binding of 1,25D3 to
ED-71 is H1. This observation is consistent with comparison of
the two co-crystal structures.
Alfacalcidol is a precursor of 1,25D3 and lacks only a hydroxyl
group at the C-25 position (Figure 1A). Interestingly, a very
distinct HDX profile was obtained for the VDR/alfacalcidol
complex when compared with VDR/1,25D3 and VDR/ED-71
Table 1. Comparison of the Conformational Dynamics Induced by Different VDR Modulators between VDR-LBD and Full-Length VDR/
RXR Heterodimer
Sequence AA Position Structure VD3 ED-71 Alfacalcidol
VDR-LBD VDR/RXR VDR-LBD VDR/RXR VDR-LBD VDR/RXR
SLRPKLSEEQQRIIA 119-133 (+2) Hinge/H1 -2 * -2 * -3 *
SLRPKLSEEQQRIIA 119-133 (+3) Hinge/H1 -3 * -2 * -4 *
ILLDAHHKTYDPTYSDF 134-150 (+2) H1 -29 -27 -24 -20 -28 -25
ILLDAHHKTYDPTYSDF 134-150 (+3) H1 -30 -28 -23 -22 -28 -26
LELSQL 219-224 (+1) LOOP 1 1 1 0 0 0
SMLPHLADL 225-233 (+2) H3 -85 -85 -80 -78 -57 -58
VSYSIQKVIGF 234-244 (+2) H3 -68 -70 -67 -68 -67 -67
FAKMIPGFRDLTSED 244-258 (+3) H3/H4 0 0 -1 1 0 0
FAKMIPGFRDLTSEDQ 244-259 (+2) H3/H4 1 0 1 1 0 0
AKMIPGFRDLTSED 245-258 (+3) H3/H4 1 0 -2 0 -1 0
AKMIPGFRDLTSEDQ 245-259 (+2) H3/H4 1 0 1 0 0 0
IVLLKSSAIE 260-269 (+2) H4/H5 -12 -13 -12 -13 -5 -7
IVLLKSSAIEV 260-270 (+2) H4/H5 -10 -12 -10 -11 -4 -6
LRSNESF 273-279 (+2) H5 -74 -74 -66 -69 -69 -71
RSNESFTMDDMS 274-285 (+2) H5/S1 -51 -48 -49 -46 -49 -46
WTCGNQDYKYRVSDVTKAGHSLE 286-308 (+3) S2/H6/H7 -33 -32 -28 -29 -10 -13
VTKAGHSLE 300-308 (+2) LOOP -31 -39 -28 -37 -1 -5
LIEPLIKF 309-316 (+1) H7 -47 -46 -47 -44 -31 -32
LIEPLIKF 309-316 (+2) H7 -52 -52 -49 -54 -33 -40
LIEPLIKFQVGLKKLNL 309-325 (+3) H7/H8 -51 -48 -48 -45 -47 -43
LIEPLIKFQVGLKKLNLHEEE 309-329 (+3) H7/H8 -38 -36 -37 -34 -34 -32
LIEPLIKFQVGLKKLNLHEEEHVLL 309-333 (+3) H7/H8 -30 -29 -28 -26 -26 -25
QVGLKKLNL 317-325 (+2) H7 -50 -48 -48 -46 -49 -45
QVGLKKLNLHEEE 317-329 (+2) H7/H8 -33 -29 -32 -27 -33 -27
ICIVSPDRPGVQDAAL 336-351 (+2) H8/H9 -2 -4 -2 -3 -1 -2
IVSPDRPGVQDAAL 338-351 (+2) H8/H9 -3 -5 -3 -5 -2 -3
IEAIQDRLSNTLQT 352-365 (+2) H9 -1 -2 -1 -1 -1 -2
AIQDRLSNTLQT 354-365 (+2) H9 -2 -3 -2 -2 -2 -2
YIRCRHPPPGSHLL 366-379 (+2) H9/H10 -1 -3 -1 -3 -1 -3
YIRCRHPPPGSHLL 366-379 (+3) H9/H10 0 -3 1 -3 0 -3
YIRCRHPPPGSHLLYAKM 366-383 (+3) H9/H10 0 -4 1 -3 0 -3
YIRCRHPPPGSHLLYAKM 366-383 (+4) H9/H10 0 -4 1 -4 0 -3
IQKLAD 384-389 (+2) H10 5 -2 6 -2 3 -2
IQKLADL 384-390 (+2) H10 4 -1 4 -3 2 -1
IQKLADLRSLNEEHSKQYRC 384-403 (+3) H10/H11 -26 -37 -21 -36 -2 -9
IQKLADLRSLNEEHSKQYRC 384-403 (+4) H10/H11 -25 -38 -22 -38 -3 -11
LRSLNEEHSKQYRC 390-403 (+2) H11 -37 -50 -33 -44 -3 -9
RSLNEEHSKQYRC 391-403 (+2) H11 -41 -50 -37 -48 -4 -9
LSFQPECS 404-411 (+1) LOOP -5 -4 -3 -4 1 0
SMKLTPLVL 411-419 (+2) H12 -27 -31 -22 -25 -1 -4
MKLTPLVL 412-419 (+2) H12 -34 -37 -31 -31 -2 -8
≤10 ≤5 ns ≥-5 ≥-10 ≥-20 ≥-30 ≥-40 <-40
The values represent the average difference in percentage of deuterium incorporation of apo VDR-LBD and apo full-length VDR/RXR in presence of
difference VDRmodulators across all H/D exchange time points (%). The regions with statistically significant differential deuteration level were colored.
Statistical summary from a two-way ANOVA between apo and ligand bound data, p < 0.001. The value in parentheses represents the charge state of
the peptide ion. Exchange kinetics for 41 different regions of the receptor LBD were measured and shown in Figure S2. See also Figure S1.
aThis exact peptide representing the hinge/H1 region (residues 119–133), the very N terminus of VDR-LBD, was not identified in the HDX study of
full-length VDR/RXR heterodimer, as a different peptide is generated covering this region in the full-length protein.
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HDX Reveals Modulator-Receptor Interactionscomplexes (Table 1 and Figure 4). Although there is no
VDR-LBD/alfacalcidol X-ray structure available, we can predict
the interactions between the protein and the ligand from HDX
data. The regions 134–150 (H1), 234–244 (H3), 317–329
(H7-H8) present a similar reduction in deuterium incorporation
induced by alfacalcidol compared to that induced by 1,25D3
and ED-71 (Table 1 and Figure 4; Figure 2S). This indicates
that similar contacts are formed between the A, secoB, and
C/D ringswith the LBP of VDR. A feature of the alfacalcidol ligand
compared with 1,25D3 and ED-71 is the notable absence of the
25-OH group. The crystal structure of VDR agonists (Hourai
et al., 2006; Rochel et al., 2000; Tocchini-Valentini et al., 2004)
reveals that 25-OH forms hydrogen bonds with His-305 (loopStructure 18, 1332–1H6–H7) and His-397 (H11). Therefore, we expect that these
two hydrogen bonds do not exist in VDR-alfacalcidol complex,
a prediction that is supported by HDX analysis. HDX analysis
clearly indicates that H11 (residues 391–403) and the loop of
H6-H7 (residues 300–308) are not protected from exchange
following alfacalcidol binding (Table 1 and Figure 4C; Figure S2).
In fact, regions of the protein containing His-397 and Tyr-401,
which are involved in the internal stabilization of H12, remain
unchanged as compared to the apo receptor. Consequently,
H12 remains in a highly dynamic state when bound to alfacalci-
dol. Moreover, the unprotected His-305 also increases the
flexibility of the adjacent region (residues 309–316) which shows
much higher protection following binding of 1,25D3 and ED-71.341, October 13, 2010 ª2010 Elsevier Ltd All rights reserved 1337
Figure 4. Average Differential HDX of Each
Ligand Mapped onto Corresponding VDR-
LBD/Ligand Crystal Structures
(A) 1,25D3 (PDB: 1DB1), (B) ED-71 (PDB: 2HAR),
(C) Alfacalcidol (PDB: 1DB1, since there is no
VDR-LBD/alfacalcidol crystal structure available).
The color legend shows the differential HDX
between Apo VDR-LBD and ligand-bound ones.
The regions in the crystal structure colored as
white are not covered in this study.
See also Figures S1 and S3.
Structure
HDX Reveals Modulator-Receptor InteractionsThe region 225–233 (H3) also showed relatively lower protection,
indicating the weaker interaction made in the alfacalcidol
complex. These data suggest that although alfacalcidol binds
to VDR, it is likely to display significant deficiency in AF-2 depen-
dent transactivation and/or LXXLL-containing cofactor peptide
interactions since it would be unable to stabilize and establish
the proper cofactor interface. Hence, 25-hydroxylation is
required to stabilize H12 and facilitate subsequent coactivator
interaction at AF2.
Differential HDX of Full-Length VDR in the Context
of VDR/RXR Heterodimer
Having completed a thorough analysis of VDR LBD ligand
complexes, we sought to compare these HDX profiles with
that of full-length VDR to determine if observations made
using the isolated LBD could be translated to the full-length
receptor. Somewhat problematic, full-length homodimeric
VDR was found to be unstable in the absence of ligand making
comprehensive HDX analysis impossible. As expected, addi-
tion of full-length RXRa to full-length VDR resulted in the
formation of a stable complex even in the absence of ligand.
Therefore, comprehensive HDX studies where performed on
the heterodimeric complex in the absence and presence of
ligands.
HDX data for VDR LBD/ligand and full-length VDR/RXR/ligand
complexes are shown in Table 1. Interestingly, the HDX profiles
for the LBD and the full-length complexes upon binding each of
the three ligands are very similar. The magnitude of protection
to exchange observed in most regions of the LBD was surpris-
ingly similar with the some exceptions. For instance, subtle
differences were observed in a region of the receptor that
contains H8 and H9 (5% difference in magnitude of protec-
tion). However, a larger difference in protection was observed
for the region of the receptor that contains H10 and H11 region
(16% difference in magnitude of protection). It is important to
note that these regions of the LBD are within or directly adjacent
to the dimerization interface of VDR/RXR. These results suggest
that the addition of ligand drives stronger interaction of VDR
with RXR resulting in the formation of a more stable protein
complex.1338 Structure 18, 1332–1341, October 13, 2010 ª2010 Elsevier Ltd All rights reservedDISCUSSION
To examine themechanism of ligand acti-
vation of VDR, we employed comprehen-
sive differential HDX to study the confor-
mational dynamics of VDR in theabsence and presence of these three well-characterized VDR
ligands. Analysis of the HDX profile of 1,25D3 in complex with
VDR reveals that a majority of the LBD protection is consistent
with the co-crystal structure of VDR-LBD bound to 1,25D3. For
instance, regions within the LBP of VDR that are in proximity
and can make efficient hydrogen bonds to 1,25D3 were highly
protected from exchange. In addition, it was observed that
regions within the LBP that make Vander Wall contacts with
ligand, such as L309, were also protected from exchange. Inter-
estingly, regions remote of the LBP, such as 317–325 (H7-H8)
and 384–390 (H10), had altered HDX kinetics, a result that could
not have been predicted from the VDR-LBD/1,25D3 co-crystal
structure. Both of these two regions are located within the dimer-
ization interface of the VDR/RXR complex; thus, we hypothesize
that the ligand-dependent perturbation of this region impacts
VDR interaction with RXR resulting in an overall stabilization of
the VDR/RXR heterodimer.
Comparison of VDR LBD 1,25D3, and ED-71 Complexes
The HDX profile of ED-71 was very similar to that of 1,25D3, with
the exception of reduced protection in H1 (Table 1). It is possible
that the small but statistically significant difference in HDX
protection reflects the mechanistic differences of the two
compounds that accounts for their different transcriptional activ-
ities and pharmacological properties. There have been many
structural and biological studies addressing the important roles
of H3, H5, and H12 in NR function (Danielian et al., 1992; Zhang
et al., 1999, 2005), and although H1 has not been addressed as
intensively there have been reports indicating that H1 plays an
important role in LBD function (Pissios et al., 2001; Wu et al.,
2002). Additionally, a recent study using HDX to characterize
various PPARg ligands showed differential protection in H1 of
that receptor (Chalmers et al., 2007). Regardless, further studies
such as mutagenesis will help to investigate the role of H1 in
ligand-dependent transcriptional output of VDR.
Unique Binding Mode of Alfacalcidol
While there is no co-crystal available for VDR in complex with
alfacalcidol, insight into its binding mode can be inferred from
its HDX profile. It is evident that the lack of 25-hydroxylation of
Structure
HDX Reveals Modulator-Receptor Interactionsalfacalcidol results in a significantly different HDX profile for this
ligand as compared with 1,25D3 and ED-71. Interestingly, in
complex with alfacalcidol, H12 of VDR is not stabilized as
compared with the apo receptor. It has been demonstrated
that H12 is critical for cofactor protein interaction and ultimately
the transcriptional output of the receptor. Furthermore, it is
hypothesized that the position of H12 is the critical switch of
the receptor between the inactive and active state. While HDX
does not provide direct information on the location of H12, it
does indicate its relative stability. Thus, the apo-like dynamics
of H12 in both LBD and heterodimer HDX profiles with VDR/alfa-
calcidol suggests that alfacalcidol is deficient in its ability to
stabilize H12 (Table 1 and Figure 4C). This lack of stability would
impair the receptors ability to stimulate the classical AF-2-
dependent VDR transactivation activity. In agreement with the
generated HDX profile we demonstrate that alfacalcidol, by
comparison to 25-hydroxylated 1,25D3 and ED-71, clearly lacks
full capacity to interact with LXXLL-containing cofactor peptides
as well as displays significantly decreased efficacy consistent
with partial agonist activity. Interestingly, biochemical-based
cofactor interaction assays display a much greater loss in effi-
cacy relative to 1,25D3 relative to the cell-based assay. We
postulate that this distinction may occur due to presence of
25-hydroxylase (CYP2R1) activity in HEK293 cells (Cheng
et al., 2003, 2004), resulting in the efficient conversion of alfacal-
cidol to 1,25D3 and therefore able to obtain maximal 1,25D3-like
efficacy with increasing treatment dose of alfacalcidol.
In addition to H12, regions of the receptor contained within H7
(residues 309–316) were also less protected to exchange upon
binding alfacalcidol as compared with 1,25D3 and ED-71. This
is likely due to the absence of hydrogen bond between an adja-
cent region containing His 305 and the 25-OH of 1,25D3 and
ED-71. Helix 7 is located at the interface of the dimer of VDR
and RXR. Thus, the change in receptor dynamics of this region
also suggests a more dynamic, less stable VDR/RXR hetero-
dimer and is another unique feature exhibited by the partial
agonist-bound VDR.
To better understand the interaction of alfacalcidol with VDR,
docking studieswere performed. As shown in Figure S3, docking
suggests very good overlap of alfacalcidol with the active confor-
mation of 1,25D3. However, the actual orientation of alfacalcidol
in the LBP is predicted to be different from that of 1,25D3.
Specifically, the three hydroxyl groups (1-OH, 3-OH, and
25-OH) of 1,25D3 and ED-71 should act as anchoring points to
form hydrogen bonds with residues within the LBP (Figures 4A
and 4B). This would result in an elongated, curved ligand that
comes in close contact with H3 (Rochel et al., 2000). HDX anal-
ysis would suggest that alfacalcidol is not elongated and curved
within LBP, and consequently does not come in proximity to H3,
as it only has two anchoring points (1-OH and 3-OH) on the same
end of the molecule (ring A). This deviation might explain the
reduced protection to exchange observed for H3 in the VDR/al-
facalcidol complex as compared with 1,25D3 and ED-71.
Comparison of Ligand-Receptor Dynamics of VDR LBD
with Full-Length VDR/RXR Heterodimer
Initial experiments demonstrated that full-length apo VDR, upon
binding its cognate coreceptor RXR, forms a stable apo hetero-
dimer complex that is amenable to detailed HDX analysis,Structure 18, 1332–1whereas the apo homodimer of VDR was not. Upon comparison,
the HDX profiles for VDR LBD/ligand complexes were similar to
those from analysis of full-length VDR/RXR/ligand complexes.
However, the subtle differences in the HDX profiles are
intriguing. The VDR/RXR dimerization interface showed higher
protection by the ligands in the full-length receptor compared
with the LBD alone, especially in H10-11 (Table 1). This
enhanced protection in the full-length receptor is attributed to
the increased interactions between VDR and RXR, indicating
that ligand binding influences heterodimer interactions in solu-
tion. This notion is more obvious when comparing the VDR
LBD/alfacalcidol and the VDR/RXR/alfacalcidol complexes. In
the VDR LBD complex, alfacalcidol does not impact the
dynamics of H11 and H12 displaying apo-like HDX behavior
due to the lack of 25-hydroxyl moiety on the ligand. Yet, in the
VDR/RXR/alfacalcidol complex modest protection to exchange
is observed likely arising from overall stabilization of the hetero-
dimeric receptor complex. Thus, ligand binding indirectly imp-
acts AF-2 dynamics via stabilization of the dimer interaction.
In summary, we have demonstrated that subtle differences in
the chemical structure of VDR ligands can elicit distinct interac-
tions within the receptor as determined by HDX. These obs-
ervations are consistent with co-crystal structures and with
biochemical and cellular assays. The perturbation in receptor
dynamics induced by ligand binding to the isolated LBD as
observed by HDX are well maintained in the full-length hetero-
dimer complex with the only deviations arising from within the
VDR/RXR dimer interface. The HDX studies presented here
provide novel insight into the molecular mechanisms of ligand
activation of VDR and this new information may prove useful
toward the design and development of VDR modulators with
discriminate mechanistic behavior.
EXPERIMENTAL PROCEDURES
Reagents
The luciferase reporter 4 3 VDRE containing a multimerized DR3 (AGGTCA
tgaAGGTCA) is a kind gift from Dr. Ana Aranda. The full-length VDR cDNA
was cloned into an expressible vector pCMV-Sport 6 vector (Invitrogen).
1,25D3 was purchased from Sigma (St. Louis, MO). ED-71 and alfacalcidol
are from Lilly Research Laboratories (Indianapolis, IN).
Cell Culture and Transcriptional Assays
Luciferase reporter assays were conducted using a multimerized VDRE lucif-
erase reporter cotransfected with/or without a full-length VDR construct into
HEK293T cells (Kumar et al., 2010). Cells were seeded at 11.5 3 106 cells
in a 6 cm cell culture plate (Corning) in DMEM with 10% heat-inactivated
FBS (GIBCO BRL, Rockville, MD). Cells were transfected at a 3:1 ratio of
fugene to DNA and 3 mg total amount of DNA was used for transfection. In
detail, on day 1, 1.5 mg of reporter (4xVDRE-luc) was cotransfected with 1.5
mg of corresponding plasmid (VDR) or with an equivalent amount of empty
vector. On day 2, transfected cells were transferred to a 384-well tissue culture
plate and the medium was replaced with DMEM+10% FBS. Four to five hours
later, cells were treatedwith compounds at 10 and 100 nMor DMSO.On day 3,
luciferase activity was measured using Britelite (Perkin Elmer).
Luminex-Based Cofactor Peptide Interaction Assays
A luminex-based biochemical assay (Berrodin et al., 2009) was used to assess
the interaction of the receptor and cofactor drived by ligands. Thirty-three bio-
tinylated cofactor peptides were synthesized by Anaspec, Inc. (San Jose, CA).
Amino acid peptide sequence design was based upon known LXXLL or
LXXLL-like amphipathic helical cores from known NR cofactor proteins. Low
capacity streptavidin beads were purchased from Radix Biosolutions341, October 13, 2010 ª2010 Elsevier Ltd All rights reserved 1339
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HDX Reveals Modulator-Receptor Interactions(Georgetown, TX). To couple peptides to beads, 50 mg/ml working concentra-
tions of peptides was prepared in distilled H2O and used to couple to strepta-
vidin beads overnight at 4C. All bead/peptide conjugates were washed twice
with PBS/BSA buffer (10 mMNaH2PO4, 150 mMNaCl, 0.1% (w/v) BSA, 2 mM
DTT [pH 7.4]) and resuspended in 600 ml of PBS/BSA buffer. All bead/peptide
conjugates were mixed into a single homogenous bead mix prior to addition to
the VDR/RXR/anti-Flag-Alexa532 complex. Alexa532 fluor-conjugated anti-
Flag M2 antibody from Sigma (St. Louis, MO) was diluted to a final concentra-
tion of 0.8 mg per ml in 13 luminex buffer (25 mM HEPES, 100 mMNaCl, 0.1%
BSA, 2 mM DTT [pH 7.4]). For each 96-well luminex reaction, 10 ml of anti-Flag
M2-Alexa532 antibody was added to 10 ml of 253WT full-length His-hVDR (60
nM final) and Flag-hRXRa (40 nM final). VDR/RXR/anti-Flag antibody complex-
ing was allowed to occur for a minimum of 30 min prior to addition of 220 ml
cofactor peptide bead mix. Ten microliters of 253 VDR ligands (1 mM final)
was added to the appropriate wells. For each 250 ml VDR/ligand/RXR/cofactor
peptide luminex reaction, interactions were allowed to proceed for approxi-
mately 3 hr with shaking at room temperature. Quantification of cofactor
peptide interaction was obtained by xMAP technology using the Bio-Plex
200 System and Suspension Array Platform (BioRad Laboratories, Hercules,
CA).
Quantitative Alphascreen-Based Cofactor Peptide Interaction
Assays
Alphascreen assays (Rouleau et al., 2003) were performed in green-filtered
light conditions in an aqueous assay buffer of PBS (pH 7.2), 0.1% BSA, and
2% DMSO in 384-well low volume white polystyrene assay plates (Greiner
America #784705). Serial dilutions of 1a, 25 di-hydroxy vitamin D3, ED-71,
or alfacalcidol were prepared in polypropylene plates and transferred to assay
plates containing WT full-length His-hVDR (30 nM final). WT full-length
Flag-hRXRa (5 nM final) was combined with 10 mg/ml anti-flag acceptor and
streptavidin donor Alphascreen beads (Perkin Elmer #6760613) and added
to the assay plates. Finally, either biotinylated DRIP 205-2 peptide (20 nM final)
(DRIP205-2: Biotin- KGGTPPPVSSMAGNTKNHPMLMNLLKDNPAQDF) or
biotinylated SRC1-NR2 peptide (30 nM final) (SRC1-NR2: Biotin-KGGGG
SCPSSHSSLTERHKILHRLLQEGSPSDI) was added and plates were incu-
bated 15 min at room temperature before reading on an Envision 2103
multilabel reader (Perkin Elmer).
Protein and Reagents for HDX Analysis
His-hVDR LBD (residues 118–425, D[165–215]) was expressed in Escherichia
coli and purified via a three step purification Ni-NTA/Refolding/Q Sepharose
FastFlow (QFF) chromatography. The final protein buffer is 10 mM Tris (pH
8.0), 200 mM NaCl, 2 mM DTT. Full-length WT His-hVDR and WT Flag-hRXRa
were expressed in Baculovirus system and purified by Ni-NTASEC or Flag/
SEC, respectively. The final protein buffer is 50 mM Tris (pH 8), 150 mM
NaCl, 10% glycerol, and 2 mM DTT. The purity for each protein was >95%,
and identification of the protein was verified using SDS-PAGE and MALDI
mass spectrometry. All purified proteins contained the epitope tag at the N
terminus. For HDX analysis, VDR LBDwas incubated with compound at a ratio
of 1:10 for 1 hr on ice. The concentration of protein stock was 14 mM. For the
full-length HDX analysis, the heterodimer complex was formed by mixing VDR
and RXRa at 1:1 molar ratio and the final concentration for each receptor was
10 mM, respectively. VDRmodulators were added at 10-fold molar excess to
receptor.
Hydrogen/Deuterium Exchange Mass Spectrometry
Differential, solution phase HDX experiments were performed with a LEAP
Technologies Twin HTS PAL liquid handling robot interfaced with an Orbitrap
mass spectrometer (Exactive, ThermoFisher Scientific) (Chalmers et al.,
2006). Each exchange reaction was initiated by incubating 4 ml of protein
complex (with or without VDR modulators) with 16 ml of D2O protein buffer
for a predetermined time (10, 30, 60, 300, 900, and 3600 s) at 4C. The
exchange reaction was quenched by mixing with 30 ml of 3 M urea, 1% TFA
at 1C. The mixture was passed across at an in-house packed pepsin column
(2 mm 3 2 cm) at 200 ml/min and digested peptides were captured onto
a 2 mm 3 1cm C8 trap column (Agilent) and desalted (total time for digestion
and desalting was 2.5 min). Peptides were then separated across a 2.1 mm3
5 cm C18 column (1.9m Hypersil Gold, Thermo Scientific) with linear gradient of1340 Structure 18, 1332–1341, October 13, 2010 ª2010 Elsevier Ltd4%–40% CH3CN, 0.3% formic acid, over 5 min. Protein digestion and peptide
separation were performed within a thermal chamber (Me´cour) held at 1C to
reduce D/H back exchange. Mass spectrometric analyses were carried out
with capillary temperature at 225C, and data were acquired with a measured
resolving power of 65,000 at m/z 400. Three replicates were performed for
each on-exchange time point.
Peptide Identification and HDX Data Processing
MS/MS experiments were performed with a linear ion trap mass spectrometer
(LTQ, ThermoFisher). Product ion spectra were acquired in a data-dependent
mode and the five most abundant ions were selected for the product ion anal-
ysis. The MS/MS *.raw data files were converted to *.mgf files and then
submitted to Mascot (Matrix Science, London, UK) for peptide identification.
Peptides included in the peptide set used for HDX had a MASCOT score of
20 or greater. The MS/MS MASCOT search was also performed against
a decoy (reverse) sequence and ambiguous identifications were ruled out.
The MS/MS spectra of all of the peptide ions from the MASCOT search
were further manually inspected, and only those verifiable are used in the
coverage. The intensity weighted averagem/z value (centroid) of each peptide
isotopic envelopes were calculated with a new version of our in-house devel-
oped software; HD Desktop (Pascal et al., 2009). The deuterium level was
calculated as described previously (Zhang and Smith, 1993). Deuterium level
(%) = {[m(P)  m(N)]/[m(F)  m(N)]} 3 100%, where m(P), m(N) and m(F) are
the centroid value of partly deuterated peptide, nondeuterated peptide, and
fully deuterated peptide, respectively. The corrections for back-exchange
were made based on an estimated 70% deuterium recovery and accounting
for the known 80% deuterium content of the on-exchange buffer.
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